Invesco Biotechnology & Genome ETF
PBE
102 hedge funds and large institutions have $92.4M invested in Invesco Biotechnology & Genome ETF in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 35 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
2% more funds holding
Funds holding: 100 → 102 (+2)
0% less capital invested
Capital invested by funds: $92.8M → $92.4M (-$388K)
1.43% less ownership
Funds ownership: 36.06% → 34.63% (-1.4%)
60% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.2M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$584K |
| 3 |
GM
GeoWealth Management
Chicago,
Illinois
|
+$462K |
| 4 |
Two Sigma Investments
New York
|
+$429K |
| 5 |
Goldman Sachs
New York
|
+$405K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GKWIM
Gerber Kawasaki Wealth & Investment Management
Santa Monica,
California
|
-$6.65M |
| 2 |
Morgan Stanley
New York
|
-$2.07M |
| 3 |
LPL Financial
San Diego,
California
|
-$703K |
| 4 |
CW
CreativeOne Wealth
Overland Park,
Kansas
|
-$510K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$460K |
PBE Hedge Fund Activity: Q3 2024 in Review
102 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2024, worth a combined $92.4M — down 0.42% from $92.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PBE positions and 7 closed out — a net gain of 2 holders — while 14 added to existing stakes and 35 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.2M. The largest seller was Gerber Kawasaki Wealth & Investment Management, cutting an estimated $6.65M.
- 102 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2024, up from 100 in Q2 2024.
- Funds reported $92.4M of Invesco Biotechnology & Genome ETF stock for Q3 2024, down 0.42% quarter-over-quarter.
- 9 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2024 and 7 closed out, a net change of +2 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q3 2024 was Susquehanna International Group, an estimated $1.2M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q3 2024 was Gerber Kawasaki Wealth & Investment Management, an estimated $6.65M sold.
Based on aggregated 13F filings for Q3 2024.